Skriv här det du söker efter!

Intercepting the Siglec-mediated interactions in cancer and inflammation

Intercepting the Siglec-mediated interactions in cancer and inflammation

Time:

1.9.2021–31.8.2023

Coordinator/main contractor:

Åbo Akademi

Financiers:

  • Finlands Akademi
  • Budget:

    250 000 euro

    Åbo Akademi University's share of the budget:

    250 000 euro (100%)

    One of the major scopes of the project is to shed light on the “dark matter of the biological universe”, the glycans, recognized by Sialic acid-binding immunoglobulin (Ig)-like lectin 9 (Siglec-9) in inflammation and cancer. Siglec-9 regulates the innate and adaptive immune systems by recognizing sialic acids on the surface sialoglycans of its binding partners. These interactions have a role in many infectious diseases, inflammation, neurodegeneration, autoimmune diseases, and cancer, which makes the sialic acid–Siglec axis an emerging target to prevent or affect these diseases.

    The project aims to unveil the multivalent Siglec-9 interactions and design novel inhibitors that block all Siglec-9-mediated interactions in inflammation and cancer. The designed inhibitors will serve as a starting point for the development of anti-inflammatory and anti-cancer agents.

    Kontakta oss

    Tiina Salminen

    Professor 

    i biokemi

    Biokemi

    Fakulteten för naturvetenskaper och teknik